Refine by
Locations
- Europe
- Albania
- Andorra
- Austria
- Belarus
- Belgium
- Bosnia & Herzegovina
- Bulgaria
- Croatia
- Cyprus
- Czech Republic
- Denmark
- Estonia
- Faroe Islands
- Finland
- France
- Germany
- Greece
- Hungary
- Iceland
- Ireland
- Italy
- Kosovo
- Latvia
- Liechtenstein
- Lithuania
- Luxembourg
- Macedonia
- Malta
- Moldova
- Monaco
- Montenegro
- Netherlands
- Northern Ireland
- Norway
- Poland
- Portugal
- Romania
- San Marino
- Serbia
- Slovakia
- Slovenia
- Spain
- Sweden
- Switzerland
- Turkey
- Ukraine
- United Kingdom
- Vatican City
Precision Engineered Medicines Technology In Europe
4 companies found
Technologybased inBresso, ITALY
At BiomimX we develop clinically relevant and fast responsive technology driven solutions tailored made to fit applications in Big Diseases. Integrating 3D cell culture and mechanical stimulation, BiomimX proposes the next generation of beating ...
Technologybased inDijon, FRANCE
Oncodesign is a biopharmaceutical company that offers you powerful technologies and tools to guide you through the development of your drug, from medicinal chemistry to drug candidate. Our therapeutic areas are expanding. In addition to oncology, ...
Oncodesign’s Pharmimage® technology module is a pharmaco-imaging module designed to monitor the effect of treatments and to define effective translational biomarkers in precision medicine. It includes translational, optical ...
Technologybased inNeuchâtel, SWITZERLAND
1DROP’s goal is to improve patient lives by enabling personalized healthcare through non-invasive diagnostic tests providing actionable health information that is accessible to everyone at any time. 1DROP facilitates the early detection, prevention ...
Technologybased inGeneve, SWITZERLAND
STALICLA has developed the first neurodevelopmental disorder-specific precision medicine discovery platform with an initial application in autism spectrum disorder (ASD). Until now, patient diagnosis and drug development for ASD and other NDDs have ...
STALICLA’s precision medicine approach begins with ‘endophenotyping’-identifying the nonbehavioral physical and molecular presentations of NDDs and characterizing subgroups of patients with similar disease signatures. DEPI matches ...